ClinicalTrials.gg

Program

Methadone

Also written as “methadone” and “fosamprenavir + ritonavir + methadone”.

Its studies are mostly in Infections · Hepatitis C · Pain · Opioid-Related Disorders · Hepatitis C, Chronic, led by 4 companies.

Furthest: phase 4, since Jan 17, 20064 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Indivior Pharmaceuticals10 open or runningphase 4since Jan 17, 2006Jan 17, 2006none ahead
Johnson & Johnson10 open or runningphase 1since Jul 2, 2009Jul 2, 2009none ahead
Lyndra10 open or runningphase 1since Jan 20, 2022Jan 20, 2022none ahead
RECORDATI GROUP10 open or runningphase 3since Feb 14, 2013Feb 14, 2013none ahead

Also a collaborator on its studies: Vertex Pharmaceuticals, aesca-pharma-gmbh, basilea-pharmaceutica-international-ltd and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 17, 2006First study: phase 4 study in Hepatitis C, ChronicNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT00279565 · 128 enrolled
  2. Jul 2, 2009Johnson & Johnson's first study: phase 1 study in Healthy ParticipantsNew to Johnson & JohnsonJohnson & Johnson · NCT00933283 · 18 enrolled
  3. Feb 14, 2013RECORDATI GROUP's first study: phase 3 study in Pain Related to CancerNew to RECORDATI GROUPRECORDATI GROUP · NCT01793480 · 146 enrolled · France
  4. Jan 20, 2022Lyndra's first study: phase 1 study in Opioid-Related DisordersNew to LyndraLyndra · NCT05251376

TargetBeta

OPRM1 →read by rule
“Mu opioid receptor agonist”ChEMBL 37, by rule

Other programs on OPRM1

ProgramCompanyFurthest phaseStudies
OxycodoneruleMundipharmaphase 472
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
cebranopadolruleTris Pharmaphase 318
axelopranruleglycyx-therapeuticsphase 28
AlfentanilruleSichuan Kelun Pharmaceuticalphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05251376Opioid-Related Disorders1WithdrawnLyndraDec 19, 20220
NCT01793480Pain Related to Cancer · France3CompletedRECORDATI GROUPMay 6, 2014146
NCT00933283Healthy Participants1CompletedJohnson & JohnsonNov 200918
NCT00279565Hepatitis C, Chronic4TerminatedIndivior PharmaceuticalsFeb 2007128

How it is read

Names in the registry

  • “Methadone”, 12 entries
  • “methadone”, 3 entries
  • “fosamprenavir + ritonavir + methadone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.